EWTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EWTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Edgewise Therapeutics does not have enough data to calculate Degree of Operating Leverage.
The historical data trend for Edgewise Therapeutics's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edgewise Therapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Degree of Operating Leverage | Get a 7-Day Free Trial | - | - | - | - | - |
Edgewise Therapeutics Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Degree of Operating Leverage | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Edgewise Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Edgewise Therapeutics's Degree of Operating Leverage falls into.
Edgewise Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:
Degree of Operating Leverage | = | % Change in EBIT** | / | % Change in Revenue |
= | ( -170.038 (Mar. 2025) / -123.406 (Mar. 2024) - 1 ) | / | ( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 ) | |
= | 0.3779 | / | ||
= | N/A*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Edgewise Therapeutics (NAS:EWTX) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Thank you for viewing the detailed overview of Edgewise Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.
R Michael Carruthers | officer: Chief Financial Officer | 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
Alan J Russell | director, officer: Chief Scientific Officer | 3415 COLORADO AVE, BOULDER CO 80303 |
Behrad Derakhshan | officer: Chief Business Officer | 3415 COLORADO AVE., BOULDER CO 80303 |
Kevin Koch | director, officer: President and CEO | 3200 WALNUT ST, BOULDER CO 80301 |
John R Moore | officer: General Counsel | 3200 WALNUT ST, BOULDER CO 80301 |
Joanne M. Donovan | officer: CMO | C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director, 10 percent owner | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Marc Semigran | officer: Chief Development Officer | C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080 |
Jonathan C Fox | director | C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Orbimed Capital Gp Vi Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jonathan D Root | director | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By Business Wire • 03-11-2025
By Faizan Farooque • 04-03-2025
By GuruFocus News • 04-02-2025
By GuruFocus News • 05-09-2025
By GuruFocus News • 02-14-2025
By GuruFocus News • 04-30-2025
By Business Wire • 03-04-2025
By GuruFocus News • 03-04-2025
By PRNewswire • 05-14-2025
By Business Wire • 01-22-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.